TITLE

Voriconazole: A New Triazole Antifungal Agent

AUTHOR(S)
Johnson, Leonard B.
PUB. DATE
March 2003
SOURCE
Clinical Infectious Diseases;3/1/2003, Vol. 36 Issue 5, p630
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Voriconazole is a second-generation azole antifungal agent that shows excellent in vitro activity against a wide variety of yeasts and molds. It can be given by either the intravenous or the oral route; the oral formulation has excellent bioavailability. The side effect profile of voriconazole is unique in that non-sight-threatening, transient visual disturbances occur in ∼30% of patients given the drug. Rash (which can manifest as photosensitivity) and hepatitis also occur. The potential for drug-drug interactions is high and requires that careful attention be given to dosage regimens and monitoring of serum levels and effects of interacting drugs. Voriconazole has been approved for the treatment of invasive aspergillosis and refractory infections with Pseudallescheria/Scedosporium and Fusarium species, and it will likely become the drug of choice for treatment of serious infections with those filamentous fungi.
ACCESSION #
9424816

 

Related Articles

  • Discovery and Development of Antifungal Compounds. Kidwai, M.; Venkataramanan, R.; Rastogi, S.; Sapra, P. // Current Medicinal Chemistry - Anti-Infective Agents;Mar2003, Vol. 2 Issue 1, p27 

    Antifungal agents constitute a major part of antiinfective drugs and have been in practice since 16th century. Antifungal agents generally belong to the class of polyenes, azoles, apart from other heterocycles, organometallics, etc. Polyenes & azoles as basic moieties act by disrupting the cell...

  • Focus on. . . Voriconazole A novel azole antifungal. Florea, Naomi R.; Kuti, Joseph L.; Quintiliani, Richard // Formulary;Aug2002, Vol. 37 Issue 8, p387 

    Focuses on the azole antifungal drug, voriconazole. In vitro activity against both Candida and Aspergillus species; Formulations available; Effectiveness in the treatment of invasive aspergillosis and esophageal candidiasis; Role in the treatment of patients with neutropenic fever and other...

  • ketoconazole.  // Royal Society of Medicine: Medicines;2002, p319 

    This article presents information on ketoconazole, an (azole) antifungal drug which can be used to treat deep-seated, serious fungal infections (mycoses) and to prevent infection in immunosuppressed patients. In particular, it is used to treat resistant candidiasis (thrush), gastrointestinal...

  • Systemic antifungals: Growing rapidly. Harris, Laura // International Journal of Medical Marketing;Sep2004, Vol. 4 Issue 4, p320 

    The article focuses on the growth of systemic antifungals. The systemic antifungal market has experienced a compound annual growth rate of 11.4 percent. An increase in the incidence and severity of invasive fungal infections, combined with the launch of novel, premium priced antifungal products,...

  • Introduction to Antifungal Drugs. Dismukes, William E. // Clinical Infectious Diseases;4/1/2000, Vol. 30 Issue 4, p653 

    Presents an overview of available antifungal drugs in the United States. Side effects of polyene drugs; Advantages of the lipid formulations of amphotericin B; Limitations of the azoles drugs.

  • Candidemia en pacientes críticamente enfermos sin neutropenia: lo que el internista debe saber. Camacho-Ortiz, Adrián; Noriega, Félix H. Rositas; Jiménez, Javier Ramos // Medicina Interna de Mexico;may/jun2007, Vol. 23 Issue 3, p234 

    Candidemia is an entity that is prevalent in the hospital setting and is associated with high mortality. In the last decade there have been major epidemiological changes in Candida blood borne infections (especially non-albican species), strongly associated with the introduction of azoles....

  • Azoles: Mode of Antifungal Action and Resistance Development. Effect of Miconazole on Endogenous Reactive Oxygen Species Production in Candida albicans. Fran�ois, Isabelle E. J .A.; Cammue, Bruno P. A.; Borgers, Marcel; Ausma, Jannie; Dispersyn, Gerrit D.; Thevissen, Karin // Anti-Infective Agents in Medicinal Chemistry;2006, Vol. 5 Issue 1, p3 

    The synthetic class of azole antimycotics constitutes the largest group of antifungal agents currently in clinical use. Widespread use of azoles has led to the rapid development of multiple drug resistance, which poses a major hurdle in antifungal therapy. The generally accepted mode of action...

  • Maintenance suppressive azole antifungal regimens are a major advance in controlling recurrent vulvovaginal candidiasis. Adis International Limited // Drugs & Therapy Perspectives;Jul2004, Vol. 20 Issue 7, p7 

    Discusses several factors concerning the management of recurrent vulvovaginal candidiasis (RVVC). Systemic and topical azole antifungal agents suggested for the treatment of patients with RVVC caused by Candida albicans; Implication of ketoconazole and fluconazole for hepatotoxicity risk;...

  • Pre-clinical development of antifungal susceptibility test methods for the testing of the novel antifungal agent E1210 versus Candida: comparison of CLSI and European Committee on Antimicrobial Susceptibility Testing methods. Pfaller, Michael A.; Watanabe, Naoaki; Castanheira, Mariana; Messer, Shawn A.; Jones, Ronald N. // Journal of Antimicrobial Chemotherapy (JAC);Nov2011, Vol. 66 Issue 11, p2581 

    Objectives To compare European Committee on Antimicrobial Susceptibility Testing (EUCAST) and CLSI broth microdilution (BMD) methods for testing the novel antifungal E1210 against a recent collection of 102 clinical isolates of Candida spp. Methods Candida isolates (102) were tested by CLSI and...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics